07:00 , May 8, 2006 |  BC Week In Review  |  Company News

Bioniche, RoundTable Health Partners deal

BNC sold its Cystistat sodium hyaluronate solution to former subsidiary Bioniche Pharma Group Ltd. (County Galway, Ireland) for C$10 million ($8.2 million) in cash. Cystistat is marketed in the EU, Canada and other countries for...
08:00 , Nov 7, 2005 |  BC Week In Review  |  Company News

Bioniche, RoundTable Healthcare Partners deal

BNC sold its Bioniche Pharma Group to RoundTable for an undisclosed sum. The deal excludes BNC's Cystistat sodium hyaluronate solution, which is marketed to treat symptoms of interstitial, bacterial and radiation-induced cystitis. Bioniche Life Sciences...
07:00 , Apr 25, 2005 |  BC Week In Review  |  Clinical News

Cystistat genitourinary data

In a Spanish study in 71 patients, 14% of patients receiving weekly intravesical Cystistat plus usual care developed UTIs during their hospital stay vs. 77% of patients receiving usual care only. Data were presented at...
07:00 , Apr 25, 2005 |  BC Week In Review  |  Clinical News

Cystistat genitourinary data

Data from a Greek study in 40 women showed that 70% of women treated with Cystistat were recurrence-free at the 1-year follow-up and there was a 92.4% decrease in the number of recurrences per year....
07:00 , Aug 25, 2003 |  BC Week In Review  |  Clinical News

Cystistat sodium hyaluronate: Marketed in EU and Canada

In a double-blind, North American study in 131 evaluable patients, the response rate for Cystistat was not statistically different from placebo. While >50% of the Cystistat-treated patients met the primary endpoint of response, BNC said...
08:00 , Mar 19, 2001 |  BC Week In Review  |  Company News

Bioniche, Laboratoire Thea sales and marketing update

Thea will exclusively distribute in France BNC's Cystistat purified hyaluronan to treat interstitial cystitis. Bioniche Life Sciences Inc. (TSE:BNC), Belleville, Ontario   Laboratoire Thea, Clermont Ferrand, France   Business: Urology  ...
08:00 , Mar 12, 2001 |  BC Week In Review  |  Company News

Bioniche, UroCor sales and marketing update

BNC granted UCOR exclusive U.S. distribution rights to its Cystistat hyaluronic acid derivative for cystitis in exchange for a $750,000 upfront fee and up to $2.3 million in milestone payments. The companies will work together...
08:00 , Mar 7, 2001 |  BC Extra  |  Company News

UroCor, Bioniche urology deal

Bioniche (TSE:BNC) granted UCOR exclusive U.S. distribution rights to its Cystistat hyaluronic acid derivative for cystitis, in exchange for a $750,000 upfront fee and up to $2.3 million in milestone payments. UCOR also received an...
07:00 , Oct 9, 2000 |  BC Week In Review  |  Company News

Bioniche, Cytochemia AG sales and marketing update

Cytochemia will exclusively distribute in Germany BNC's Cystistat purified hyaluronic acid derivative. The product, which is injected into the bladder, is approved in Europe and Canada to treat cystitis. Bioniche Life Sciences Inc. (TSE:BNC), London,...
07:00 , Sep 11, 2000 |  BC Week In Review  |  Clinical News

Cystistat purified hyaluronic acid derivative regulatory update

BNC received European marketing approval for Cystistat to treat radiation cystitis and cystitis caused by infections, trauma, urolithiasis, urinary retention and neoplasia. Previously, Cystistat was marketed in Europe to treat interstitial cystitis. The product also...